View in EDS

EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines.

Saved in:
Bibliographic Details
Title: EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines.
Authors: Latarani M; Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK., Pucci P; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK., Eccleston M; Belgian Volition SPRL, Parc Scientifique Créalys, Namur, BE, Belgium.; ValiRx PLC, Medicity Nottingham, Nottingham, UK., Manzo M; Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland., Gangadharannambiar P; Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK., Fischetti I; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Alborelli I; Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland., Mongiardini V; Molecular Medicine Research Line, Fondazione Istituto Italiano di Tecnologia (IIT), Genoa, Italy., Mahmood N; Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK., Colombo MP; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Grimaldi B; Molecular Medicine Research Line, Fondazione Istituto Italiano di Tecnologia (IIT), Genoa, Italy., Rigas S; Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK., Akamatsu S; Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Hawkes C; Division of Biomedical and Life Sciences, Lancaster University, Lancaster, UK., Wang Y; Department of Experimental Therapeutics, BC Cancer/University of British Columbia, Vancouver, Canada., Jachetti E; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Crea F; Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK.
Source: Epigenomics [Epigenomics] 2025 Feb; Vol. 17 (3), pp. 145-154. Date of Electronic Publication: 2025 Jan 29.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101519720 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1750-192X (Electronic) Linking ISSN: 1750192X NLM ISO Abbreviation: Epigenomics Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39878501
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Latarani+M%22">Latarani M</searchLink>; Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK.<br /><searchLink fieldCode="AU" term="%22Pucci+P%22">Pucci P</searchLink>; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Eccleston+M%22">Eccleston M</searchLink>; Belgian Volition SPRL, Parc Scientifique Créalys, Namur, BE, Belgium.; ValiRx PLC, Medicity Nottingham, Nottingham, UK.<br /><searchLink fieldCode="AU" term="%22Manzo+M%22">Manzo M</searchLink>; Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Gangadharannambiar+P%22">Gangadharannambiar P</searchLink>; Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK.<br /><searchLink fieldCode="AU" term="%22Fischetti+I%22">Fischetti I</searchLink>; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Alborelli+I%22">Alborelli I</searchLink>; Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Mongiardini+V%22">Mongiardini V</searchLink>; Molecular Medicine Research Line, Fondazione Istituto Italiano di Tecnologia (IIT), Genoa, Italy.<br /><searchLink fieldCode="AU" term="%22Mahmood+N%22">Mahmood N</searchLink>; Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK.<br /><searchLink fieldCode="AU" term="%22Colombo+MP%22">Colombo MP</searchLink>; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Grimaldi+B%22">Grimaldi B</searchLink>; Molecular Medicine Research Line, Fondazione Istituto Italiano di Tecnologia (IIT), Genoa, Italy.<br /><searchLink fieldCode="AU" term="%22Rigas+S%22">Rigas S</searchLink>; Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK.<br /><searchLink fieldCode="AU" term="%22Akamatsu+S%22">Akamatsu S</searchLink>; Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.<br /><searchLink fieldCode="AU" term="%22Hawkes+C%22">Hawkes C</searchLink>; Division of Biomedical and Life Sciences, Lancaster University, Lancaster, UK.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; Department of Experimental Therapeutics, BC Cancer/University of British Columbia, Vancouver, Canada.<br /><searchLink fieldCode="AU" term="%22Jachetti+E%22">Jachetti E</searchLink>; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Crea+F%22">Crea F</searchLink>; Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101519720%22">Epigenomics</searchLink> [Epigenomics] 2025 Feb; Vol. 17 (3), pp. 145-154. <i>Date of Electronic Publication: </i>2025 Jan 29.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101519720 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1750-192X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%221750192X%22">1750192X </searchLink><i>NLM ISO Abbreviation: </i>Epigenomics <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39878501
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/17501911.2025.2453419
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 145
    Titles:
      – TitleFull: EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Latarani M
      – PersonEntity:
          Name:
            NameFull: Pucci P
      – PersonEntity:
          Name:
            NameFull: Eccleston M
      – PersonEntity:
          Name:
            NameFull: Manzo M
      – PersonEntity:
          Name:
            NameFull: Gangadharannambiar P
      – PersonEntity:
          Name:
            NameFull: Fischetti I
      – PersonEntity:
          Name:
            NameFull: Alborelli I
      – PersonEntity:
          Name:
            NameFull: Mongiardini V
      – PersonEntity:
          Name:
            NameFull: Mahmood N
      – PersonEntity:
          Name:
            NameFull: Colombo MP
      – PersonEntity:
          Name:
            NameFull: Grimaldi B
      – PersonEntity:
          Name:
            NameFull: Rigas S
      – PersonEntity:
          Name:
            NameFull: Akamatsu S
      – PersonEntity:
          Name:
            NameFull: Hawkes C
      – PersonEntity:
          Name:
            NameFull: Wang Y
      – PersonEntity:
          Name:
            NameFull: Jachetti E
      – PersonEntity:
          Name:
            NameFull: Crea F
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2025 Feb
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1750-192X
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Epigenomics
              Type: main
ResultId 1